Skip to main content
ENTXEntera Bio Ltd.Sell5.6·$3.31
ENTX · Why this verdict

Why Entera Bio (ENTX) is rated SELL

Updated

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis

Engine thesis — one sentence

Entera Bio is a cash-burning, single-pipeline biotech (EB613) with quality at 1.6/10 and repeated earnings misses; price momentum is positive, but no reliable analyst target exists and little upside is left to the technical target.

Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.

Thesis pillars

The pipeline is concentrated in EB613, flagged as a HIGH concentration risk, in a binary industry (biotechnology).

↓Deteriorating
Bear case
Expectation
EB613 advances through development milestones without a negative setback over 12 months.

CounterConcentration in one asset can be a strength if EB613 succeeds, since the stock would then carry outsized upside.

Entera Bio is cash-burning with negative free cash flow, no competitive moat and quality at 1.6/10, well below the 4.0 floor.

→Stable
Quality breakdown
Expectation
Cash burn narrows or funding is secured so that quality improves above 4.0 over the next 12 months.

CounterPre-revenue biotechs are expected to burn cash, and quality metrics such as margins are structurally zero until a product is approved, so the low score may overstate distress.

Recent quarterly results show 2 misses (EPS -0.11 vs -0.07 estimated, then -0.14 vs -0.08), with average surprise of -22.7%.

→Stable
Earnings
Expectation
Quarterly losses narrow to or below estimates over the next 12 months.

CounterWith estimates near -0.07 per share, small absolute differences create large percentage misses, so the percent surprise exaggerates the miss.

Momentum scores 6.1/10 with rising OBV and the price above its 200-day average, with a golden cross and bullish MACD.

↑Improving
Momentum breakdown
Expectation
The price holds above its 200-day average over the next 12 months.

CounterVolume component is scored 0.0 and the stock sits only 2.5% below the 3.22 technical target, so the breakout could stall quickly on thin volume.

The raw analyst target of $9.75 was rejected as implausible against a $3.14 price (3.1x), so no reliable analyst upside exists and the technical target is only 3.22.

↓Deteriorating
Bear case
Expectation
A credible analyst target appears or a clinical catalyst revalues the shares above the 3.22 technical target.

CounterThe rejected target reflects analysts valuing the pipeline above the current price, so the market may be significantly undervaluing the pipeline.

Per-dimension breakdown

Value

9.0/10data confidence 33%
ComponentSub-score
Analyst target9.0
  • ▸Attractively valued

Quality

1.6/10data confidence 100%
ComponentSub-score
ROE0.0
ROA0.0
Gross margin0.0
Op margin0.0
Net margin0.0
Current ratio5.0
FCF quality0.0
Moat4.8
Piotroski F4.4
  • ▸Cash-burning (FCF negative)
  • ▸No competitive moat
  • ▸Quality concerns

Growth

5.0/10data confidence 50%

Momentum

8.1/10data confidence 100%
ComponentSub-score
RSI5.0
MACD6.6
OBV10.0
MA position9.0
Volume9.7
  • ▸Volume accumulation (rising OBV)
  • ▸Above 200-day MA

Sentiment

7.5/10data confidence 100%
ComponentSub-score
Analyst rating7.1
Price target10.0
erm sentiment5.0
  • ▸Light analyst coverage (4.0) — signal dampened
  • ▸Analyst upside: 195%

Insider

5.0/10data confidence 50%

Peer rank

6.4/10data confidence 80%
ComponentSub-score
value rank5.0
quality rank6.1
growth rank5.0
  • ▸Conservative debt levels

Technical

3.2/10data confidence 100%
ComponentSub-score
bollinger1.2
support resistance2.7
52w position5.7

Risk (lower is worse)

4.5/10data confidence 100%
ComponentSub-score
short interest8.0
days to cover0.0
volatility0.0
put call10.0
implied vol0.0
max pain risk3.0
beta5.2
debt equity10.0
  • ▸High IV: 150%
  • ▸Above max pain $1
  • ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Catalyst

2.8/10data confidence 100%
ComponentSub-score
erm5.0
earnings history1.1
earnings timing5.0
surprise avg0.0
  • ▸Earnings concerns: 1B/2M

How the verdict was assembled

Engine trigger

Quality below minimum threshold.

Engine technical detail
verdict_path: L1:HARD_BLOCK:QUALITY_FLOOR
Passed (7)
  • MOMENTUM:8.1>=5.5
  • ASYMMETRY:10.1>=1.5
  • INSIDER:OK
  • NEWS_EVENTS:NONE_RECENT
  • EARNINGS_PROXIMITY:130d clear
  • SEMI_CYCLE_PEAK:CLEAR
  • MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)

none

Warning (1)
  • 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
10.05
Upside
+150.8%
Downside
15.0%
Sizing output
AVOID

SetupBreakout — Golden cross, above all MAs, RSI 60, MACD bullish

EdgeInst Constrain — Small cap ($0.6B) below institutional reach

SuitabilitySpeculative — Binary industry: Biotechnology

Investment implication

The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 10.05.

The strongest dimensions are Value at 9.0, Momentum at 8.1, and Sentiment at 7.5; the weakest are Quality at 1.6, Catalyst at 2.8, and Technical at 3.2. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 10.05 and an engine sizing output of AVOID.

What would invalidate the thesis

Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.

  • P1Cash Burning Low Quality

    Trip ifQuality score stays below 2.0 from the current 1.6 for 2 consecutive quarters.

  • P2Single Pipeline Concentration

    Trip ifEB613 share of pipeline stays above 80% with no second clinical asset.

  • P3Widening Earnings Misses

    Trip ifEPS surprise stays below -25% for 2 consecutive quarters.

  • P4Positive Technical Momentum

    Trip ifPrice falls below the 2.92 stop-loss level.

  • P5Unreliable Analyst Target

    Trip ifPrice falls below 2.50 from the current 3.14.

Engine reasoning is mechanically derived from pipeline gate outputs. See decision view.

Home › Stocks › ENTX › Why this verdict